The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 27898675.
- Also identified by DOI 10.1371/journal.pmed.1002182 and PMC identifier 5127493.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a Perspective, Jacqueline Deeen discusses challenges in balancing the individual and population risks and benefits for CYD-TDV (Dengvaxia), the first available dengue vaccine.
Medical subject headings
- Dengue
- Dengue Vaccines
- Vaccination